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Objective. Scleroderma (SSc) is an autoimmune
disease of unknown etiology. The disease is 3–8 times
more frequent in women than in men. The role of X
chromosome inactivation (XCI) in the predisposition of
women to autoimmunity has been questioned. Until now
this has not been illustrated experimentally. This study
was undertaken to test the hypothesis that disturbances
in XCI mosaicism may be involved in the pathogenesis
of the disease in female patients with SSc.
Methods. Seventy female SSc patients and 160
female controls were analyzed for the androgen receptor
locus by the Hpa II/polymerase chain reaction assay to
assess XCI patterns in DNA extracted from peripheral
blood cells. Furthermore, skin biopsy samples were
obtained from 5 patients whose blood revealed an
extremely skewed pattern of XCI, and the analysis
repeated. Since microchimerism in SSc was reported, Y
chromosome sequences were investigated in all samples.
Results. Skewed XCI was observed in DNA from
peripheral blood cells in 35 of 55 informative patients
(64%), as compared with 10 of 124 informative controls
(8%) (P < 0.0001). Extreme skewing was present in 27 of
the patient group (49%), as compared with only 3 of the
controls (2.4%) (P < 0.0001). However, XCI was random
in all skin biopsy samples. The potential contribution of
microchimerism to the random XCI pattern is highly
unlikely based on the medical histories of the patients.
Conclusion. Skewed XCI mosaicism may play a
significant role in the pathogenesis of SSc.
Scleroderma (systemic sclerosis; SSc) is an auto-
immune connective tissue disease of unknown etiology.
Although the pathogenesis is poorly understood, disease
progression involves the vasculature, the immune sys-
tem, and extracellular matrix deposition (1,2). SSc oc-
curs 3–8 times more frequently in women than in men,
and the highest incidence of the disease is in individuals
ages 45–55 years (3). Based on observations that SSc has
clinical features that resemble chronic graft-versus-host
disease, microchimerism resulting from transplacental
cells (cell passage from child to mother, or in some
instances, mother to child) was considered responsible
for autoimmune diseases, including SSc (4,5). Subse-
quently, fetal DNA and cells were identified in some
women with SSc (5–8). Despite these interesting find-
ings, microchimerism in SSc could be secondary to the
underlying disease, because it offers no explanation for
the occurrence of the disease in men or in women who
have had no children. In addition, there is no proof that
transplant recipients who are chimeric individuals are at
increased risk for SSc (9).
Loss of immunologic tolerance to self antigens is
an important feature of autoimmune disorders. T cell
tolerance, which appears to be broken in many of these
diseases, is thought to be established by negative selec-
tion against potentially self-reactive T cells in the thymic
medulla and cortex–medulla junction. Professional
antigen-presenting cells, particularly dendritic cells, me-
diate the negative selection process (10,11). It has been
demonstrated that risk of autoimmunity could be in-
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creased by a lack of exposure to self antigens in the
thymus and the presence of autoreactive T cells (12).
A potential mechanism through which lack of
exposure to self antigens could occur in women is a
disturbance in the X chromosome inactivation (XCI)
process (13–15). XCI is an epigenetic regulation in early
development that results in transcription inactivation of
1 of the pair of X chromosomes (16,17). As a result of
this physiologic event, the X chromosome inherited
from either parent is silenced at random, and normal
women are thus a mosaic of 2 cell populations. It is
therefore conceivable that skewed XCI could lead to the
escape of X-linked self antigens from presentation in the
thymus or in other peripheral sites that are involved in
tolerance induction, inadequate thymic deletion, and
finally loss of T cell tolerance. However, examination of
XCI patterns in peripheral blood from female patients
with autoimmune diseases (including systemic lupus
erythematosus [SLE], juvenile diabetes, multiple sclero-
sis, and juvenile rheumatoid arthritis) did not reveal
skewed X inactivation patterns (15,18). Conversely, dis-
turbances in the XCI process are known to alter the
clinical manifestation of X-linked disorders in women
(19,20). In addition, high frequency of skewed X inacti-
vation has been observed in breast and ovarian cancers
(21,22), and in women with recurrent spontaneous abor-
tions (23,24).
We hypothesized that extremely skewed XCI,
especially in hematopoietic stem cells, may be involved
in the pathogenesis of SSc. This hypothesis was based on
2 observations: first, the disease is more prevalent in
women than in men. Second, oligoclonal T cell expan-
sion has been documented in the skin lesions of SSc
patients (25), which may indicate an inadequate ability
to induce tolerance to self antigens, particularly
X-linked autoantigens. To test this hypothesis, we ana-
lyzed the methylation status of a highly polymorphic
CAG repeat in the androgen receptor (AR) gene, and
demonstrated that XCI mosaicism is extremely skewed
in the blood but not in the skin lesions of female patients
with SSc.
PATIENTS AND METHODS
Patients. White women diagnosed as having SSc (n 
70), rheumatoid arthritis (n  12), or SLE (n  9), and healthy
female controls with no history of autoimmune disease or
cancer (n  160) were included in the study. All patients
fulfilled the American College of Rheumatology (formerly, the
American Rheumatism Association) diagnostic criteria for
scleroderma (26), SLE (27), or rheumatoid arthritis (28). The
mean (SD) ages were 49  14 years for SSc patients (40  14
years in the nulligravid patients, and 53  12 years in the gravid
patients), 52  15 years in rheumatoid arthritis patients, 47 
15 years in SLE patients, and 46  10 years in controls. The
duration of symptoms, first appearing as Raynaud’s phenom-
enon, puffy hands, esophagitis, or dyspnea, was 10  7 years
among the SSc patients. The mean age at diagnosis was 39 
12 years. Five patients had the limited cutaneous form of
disease, and the remaining patients had diffuse disease. The
duration of the symptoms in the rheumatoid arthritis and SLE
patients was 12  7 and 9  8 years, respectively. All of the
patients had attended the rheumatology clinics of the partici-
pating institutions for at least 1 year since onset of disease. The
SSc patients were chosen randomly for the study. The rheu-
matoid arthritis and SLE patients who were subsequently
recruited were selected from the group of female patients who
were receiving immunosuppressive therapy and were age
matched with the SSc patients. The ethics review boards at the
participating institutions approved the study protocol. In-
formed consent was obtained from all subjects.
X inactivation study. XCI patterns were quantitated by
use of radioactive -33P-dCTP (NEN, Boston, MA) polymer-
ase chain reaction (PCR) as described elsewhere (29). Briefly,
DNA was extracted from 10 ml venous blood (peripheral blood
mononuclear cells), skin biopsy, buccal mucosa, and hair
follicle specimens. The methylation status of a highly polymor-
phic CAG repeat in the androgen receptor (AR) gene was
determined by use of methylation-sensitive restriction enzyme
Hpa II (MBI Fermentas, St. Leon-Rot, Germany). Male DNA
of cytogenetically verified 46XY karyotype was used as control
for complete digestion. The PCR products, both before and
after digestion, were separated on 8% sequencing gels, dried,
and were autoradiographed on Medicalfilm CP-BU (Agfa,
Mortsel, Belgium). Densitometric analysis of the alleles was
performed using Multi-Analyst software version 1.1 (Bio-Rad,
Hercules, CA). The assay was performed at least twice for each
sample. In addition, cold PCR followed by electrophoretic
separation of the alleles in 4% MetaPhor agarose (FMC
BioProducts, Rockland, ME) or 10% polyacrylamide,
ethidium bromide staining, and densitometric analysis (as
described above) were performed for all samples. The results
of the densitometric analyses included normalization of the
ratios, based upon the undigested samples. This was deter-
mined by dividing the allele ratio of the digested sample by the
ratio of the undigested sample from the same specimen. The
use of this ratio corrects for preferential amplification of 1
allele, which often occurs for the shorter microsatellite allele.
Y chromosome study. Y chromosome–specific se-
quences were analyzed by PCR and 2 independent sets of
primers. First, nested PCR with primers Y1-1  Y1-2 and
Y1-3  Y1-4 was performed as described (30). Electrophoresis
of amplicons in 1.5% agarose gel revealed a 148-bp Y
chromosome–specific fragment in positive samples. To con-
firm the results, all samples were analyzed with a second set of
PCR primers, as previously described (31). Positive (male
DNA) and negative (no DNA) controls were included in all
reactions. The results from control and test groups in XCI and
Y chromosome studies were compared by chi-square test with
Yates’ correction.
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RESULTS
PCR-based X inactivation study of peripheral
blood. XCI status was informative in 55 of the 70 SSc
patients and in 124 of the 160 controls. Some heterozy-
gous individuals were considered uninformative since
only those whose alleles resolve adequately for densito-
metric analysis were included in the study. Skewed XCI
(80% skewing) was observed in 35 of the 55 patients
(64%), and 10 of the 124 controls (8%) (P  0.0001).
More importantly, extremely skewed XCI, defined as
90% inactivation of 1 allele, was present in 27 patients
(49%), and in only 3 controls (2.4%) (P  0.0001)
(Table 1 and Figure 1A). Extremely skewed XCI is a
rare event and has been reported in 1–2% of 20–40-year
old women, and in 2–4% of 55–72-year-old women
(22–24). Since the data for SSc patients is strikingly
bimodal, we plotted the distribution of the X inactiva-
tion profiles according to age. However, we did not
observe a shift toward the skewed range in older patients
and controls (Figure 2).
Immunosuppressive therapy and X inactivation.
At the time of sample collection, 62 patients were being
treated with immunosuppressive therapies (cyclo-
phosphamide, 50 mg twice a day, n  31;
D-penicillamine, 300 mg/day, n  16; azathioprine, 50
mg twice daily, n  9; chloroquine, 200 mg/day, n  4;
methotrexate, 10 mg once a week, n  1; mycopheno-
late, 1,000 mg/day, n  1). The remaining 8 patients
were newly diagnosed and not taking any medications.
Although 6 of the 55 informative patients never received
immunosuppressive agents, and an additional 16 pa-
tients had been receiving immunosuppressive treatment
for 1 week, a major concern with the observed XCI
patterns among SSc patients was that concomitant im-
munosuppressive therapy could influence the results, as
has been observed in feline hematopoietic cells (32).
Analysis of the data on XCI patterns versus duration of
immunosuppressive therapy did not reveal a statistically
significant correlation. Among the patients with skewed
X inactivation, 8 (23%) had received immunosuppres-
sive agents for 6–10 years, 14 (40%) for 1–5 years, and 13
(37%) had received no immunosuppressive agents or
received them for 1 week. Of the patients with random
X inactivation, 4 (20%) had received immunosuppres-
sive agents for 6–10 years, 7 (35%) for 1–5 years, and 9
(45%) received no immunosuppressive agents or re-
ceived them for 1 week. Complete ablation of bone
marrow or suspended leukopenia was not observed in
any of the patients at any stage of the treatment.
In order to demonstrate that immunosuppressive
medications do not skew the XCI patterns, we collected
peripheral blood samples from patients who were being
treated with similar immunosuppressive medications,
but who had rheumatoid arthritis (n  12) or SLE (n 
9). Skewed XCI was observed in 1 rheumatoid arthritis
patient, whereas a random pattern was clearly visible in
17 patients (Figures 1B and C). Three patients were not
informative for the AR polymorphism.
Figure 1. X chromosome inactivation status in scleroderma (A), rheu-
matoid arthritis (B), and systemic lupus erythematosus (C) patients.
Polymerase chain reaction products from the androgen receptor
methylation assay demonstrate random X chromosome inactivation
patterns in samples 04-156 (allele ratio 64.6%:35.4%), 04-157 (52.8%:
47.2%), 04-158 (51.0%:48.4%), 04-171 (53.1%:46.9%), and 04-172
(50.6%:49.4%), and skewed patterns in samples 03-880 (95.4%:4.6%),
03-962 (92.6%:7.4%), and 03-900 (94.1%:5.9%). Sample 04-170 is not
informative for the androgen receptor polymorphism. For each sam-
ple, DNA was either undigested () or digested () with the
methylation-sensitive restriction enzyme Hpa II. Marker (M; pUC mix
8 [331-bp and 242-bp]) fragments are visible.






Skewed (80–90%) 8 (14.54)† 7 (5.64)
Extremely skewed
(90%)
27 (49.09)† 3 (2.41)
Total 35 (63.63)† 10 (8.05)
* Values are the number (%).
† P  0.0001 versus controls, by chi-square test.
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Pregnancy history and Y chromosome analysis.
Characteristics of the SSc patients with skewed XCI are
shown in Table 2. Y chromosome analysis was per-
formed in a blinded manner (without prior knowledge of
pregnancy history) in all patients, and Y chromosome–
specific DNA was detected in 16 (41%) of the 39
patients who were known to have at least 1 son. There
was no history of pregnancy in 23 of the patients. In the
control group, 31 women had at least 1 son and Y
chromosome–specific DNA was detected in 2 of them
(P  0.0026) (Table 3). These results are consistent with
the previous reports (7,8) of a significant difference in
persistence of male DNA in peripheral blood between
controls and SSc.
PCR-based X inactivation study of skin biopsy,
buccal mucosa, and hair follicle specimens. Skin biopsy
samples were obtained from the site of clinically detect-
able cutaneous changes in 5 patients (patients 03-894,
03-899, 03-956, 03-963, and 03-1101). Buccal mucosa
and hair follicle specimens were also collected from the
same patients, excluding patient 03-963. These patients
were selected from a group that displayed almost exclu-
sive representation for only 1 allele of the AR polymor-
phism in their methylation-sensitive PCR assay, which
indicated 90% skewed XCI. A random pattern of XCI
was observed in the skin biopsy samples of all patients,
with the allele ratios of 50.5%:49.5% in patient 03-894,
53%:47% in patient 03-899, 51.3%:48.7% in patient
03-956, 65%:35% in patient 03-963, and 54.7%:45.3%
for patient 03-1101 (Figure 3). The buccal mucosa and
hair follicle samples also revealed a random pattern in
all patients analyzed.
It has been reported that microchimeric cells can
build tissues as well as attack them (33). Therefore, it is
possible that DNA from prior pregnancies contributes to
the random XCI profile observed in the skin lesions of
the above-mentioned SSc patients. However, several
observations provide evidence against this possibility.
First, 2 of these patients (03-894 and 03-963) had never
been pregnant. Second, none of the patients with skewed
XCI in their blood had a twin sibling. Third, careful
analysis of the predigested specimens did not reveal 3
AR alleles in any of the informative patients (results not
shown).
DISCUSSION
A reduction in the sex ratio (male:female) is
characteristic for most autoimmune diseases, including
SSc, and sex differences may be of great relevance. One
such sex difference is the number of X chromosomes,
which leads to XCI mosaicism in women. In this study
we demonstrate skewed XCI patterns in peripheral
blood mononuclear cells of a significant proportion
(64%) of women with SSc. Approximately 8% of female
control subjects and 8% of rheumatoid arthritis patients
exhibit skewed X inactivation patterns (80:20), which
is consistent with previous estimates (15,22–24). The
effect is more pronounced for patterns of X inactivation
(90:10), since nearly half of SSc patients show such
skewing, compared with only a small percentage of
women in the control group. Furthermore, the skin
lesions of 5 patients with extreme skewing in blood
displayed random XCI. Our results show that factors
Figure 2. Distribution of X inactivation patterns according to age in scleroderma patients and control sub-
jects.
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associated with extremely skewed XCI are present in a
significant proportion of female patients with SSc, and
raise important questions as to the cause and conse-
quence of this observation.
Figure 3. Skewed X chromosome inactivation in samples. Polymerase
chain reaction products of undigested () (lane 1) and Hpa II–
digested () DNA from blood (lane 2) and skin biopsy samples (lane
3) of patients 03-894, 03-899, and 03-1101 are shown. Two alleles are
seen in lanes 1 and 3, whereas a single allele resulting from extremely
skewed X chromosome inactivation is clearly visible in lane 2 for all 3
samples (see text for allele ratios).
Table 2. Characteristics of the scleroderma patients with skewed X chromosome inactivation
Patient (no.) Year of birth Year of disease onset Pregnancy history* Sex and birth year of children
90% skewing
1 (03-894)† 1945 1989 G0, P0 –
2 (03-963)† 1938 1998 G0, P0 –
3 (03-879) 1966 1991 G0, P0 –
4 (03-1123) 1950 1990 G0, P0 –
5 (03-951) 1986 2003 G0, P0 –
6 (03-881) 1971 1990 G0, P0 –
7 (03-892) 1965 1993 G0, P0 –
8 (03-1112) 1963 1997 GII, PI F 1998
9 (03-899)† 1953 1998 GI, PI F 1977
10 (03-948) 1959 1989 GII, PII M 1971, M 1975
11 (03-954)‡ 1965 2000 GII, PII M 1998, F 1999
12 (03-886) 1960 1994 GII, PII M 1986, F 1989
13 (03-1120) 1950 1983 GII, PII M 1970, F 1973
14 (03-890)‡ 1956 1989 GII, PII M 1989, F 1992
15 (03-895)‡ 1941 1984 GIV, PII M 1959, F 1969
16 (03-880) 1967 2002 GII, PII F 1987, M 1990
17 (03-888) 1952 1996 GII, PII M 1973, F 1977
18 (03-962)‡ 1946 1993 GIII, PIII F 1968, F 1970, M 1973
19 (03-878) 1945 2000 GIII, PIII F 1968, F 1971, M 1977
20 (03-893)‡ 1936 1984 GIX, PIV F 1953, M 1954, F 1956, M 1962
21 (03-1110) 1932 1993 GVI, PIV F 1952, F 1954, M 1962, M 1964
22 (03-956)†‡ 1956 2001 GV, PIV F 1973, F 1975, M 1977, M 1980
23 (03-953) 1941 1995 GIV, PIV M 1967, M 1969, F 1974, F 1976
24 (03-884) 1938 1994 GVI, PIV M 1965, M 1969, F 1973, F 1975
25 (03-900)‡ 1940 1984 GVII, PV M 1955, F 1960, F 1962, M 1966, M 1974
26 (03-1101)† 1941 1993 GV, PV F 1957, F 1959, M 1963, M 1968, M 1969
27 (03-952) 1938 1984 GVI, PV M 1960, M 1964, F 1969, F 1971, F 1973
80–90% skewing
1 (03-877) 1954 1999 GII, P0 –
2 (03-1104) 1956 1983 G0, P0 –
3 (03-949) 1975 2000 G0, P0 –
4 (03-1128) 1983 2002 G0, P0 –
5 (03-943) 1942 1999 GII, PII M 1965, M 1969
6 (03-950) 1936 1982 GIV, PIV M 1953; M 1955, M 1964, F 1969
7 (03-1122) 1949 1993 GVIII, PV M 1966, F 1968, M 1970, M 1978, F 1982
8 (03-885)‡ 1933 1993 GVII, PVII F 1960, F 1961, F 1963, F 1964, F 1966, M 1968, M 1971
* G  gravida; P  para.
† Skin biopsy sample obtained.
‡ Y chromosome sequence–positive patient.
Table 3. Distribution of Y chromosome sequences in patients and





no. (%) Total, no.
Scleroderma patients 16 (41.02)† 23 (58.98) 39
Skewed XCI 9 (40.90)† 13 (59.10) 22
Random XCI 4 (36.36)† 7 (63.64) 11
Control females 2 (6.45) 29 (93.55) 31
Skewed XCI 1 (25.00) 3 (75.00) 4
Random XCI 1 (4.16) 23 (95.84) 24
* XCI  X chromosome inactivation.
† P  0.0026 by chi-square test.
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The causes of skewed XCI are classified into 2
groups: primary and secondary. Bias in the initial choice
of which X chromosome to be inactivated, due to
germline X-inactive specific transcript mutations, is an
example of a primary cause (19). Secondary causes
include deleterious X-linked mutations or X chromo-
some rearrangements, aging, twinning, or monoclonal
expansion of cells (for review, see ref. 34). Existence of
deleterious X-linked mutations or X chromosome re-
arrangements and their differential expression patterns
could provide a disadvantage to affected blood cells, but
not to skin cells in SSc patients, and lead to skewed XCI.
With respect to the consequences of skewed X
inactivation, it is well documented that clinical manifes-
tation of X-linked disorders in women could be influ-
enced by disturbances in the XCI process (35). In
addition, it has been hypothesized that skewed XCI
could be a factor influencing the predisposition of
women to autoimmunity (13,14). Because we have dem-
onstrated skewed XCI patterns in a significant propor-
tion of female SSc patients, disturbed X inactivation
mosaicism could be considered a contributing factor in
disease pathogenesis.
Although extremely skewed XCI is rare, it does
not lead to the development of SSc in all women. We
agree with the hypothesis that a subsequent event, such
as environmental exposure to viral, chemical, or other
agents, may trigger a cascade that results in SSc (8). In
addition, the coinheritance of genetic susceptibility fac-
tors, such as functional variants in vital negative regula-
tory molecules of the immune system (36), may exacer-
bate the effects of skewed XCI and contribute to the
development of autoimmune diseases, including SSc.
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